Lung Cancer
Evidence-based overview of mebendazole in lung cancer, including ERK relevance and broader signalling interest
Mebendazole has meaningful mechanistic relevance in lung cancer, especially in tumours driven by ERK / MAPK and survival-pathway signalling.
Overview
The current note set here is more mechanism-driven than trial-driven, but lung cancer remains an important fit for mebendazole because of ERK, angiogenesis, and resistance-related biology.
Key findings
ERK / MAPK signalling is frequently upregulated in NSCLC
Mebendazole's pathway effects suggest relevance in proliferation, spread, and resistance contexts
Combination strategies are likely to matter more than monotherapy in high-ERK disease
Clinical positioning
This remains an emerging fit rather than a fully developed clinical one, but it is a reasonable page to keep in the structure.
References
Mebendazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.